Aldeyra Therapeutics (ALDX) Interest Expenses (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Interest Expenses came in at $468678.0 in Q1 2026, down 94.25% YoY from $8.2 million in Q1 2025, and down 26.55% on a QoQ basis from $638060.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Interest Expenses (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Interest Expenses data on file, last reported at $468678.0 in Q1 2026.
- Quarterly Interest Expenses fell 94.25% year-over-year to $468678.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 73.25% YoY) and the FY2025 annual result came in at $6.6 million, up 35.24% from the prior year.
- Interest Expenses declined to $468678.0 in Q1 2026, from $638060.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $26.4 million in Q1 2023 to a low of $145017.0 in Q4 2023.
- A 5-year average of $5.1 million and a median of $1.6 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 8896.65% — and 2024, when it sank 98.11%.
- Tracing ALDX's Interest Expenses over 5 years: stood at $712265.0 in 2022, then plunged by 79.64% to $145017.0 in 2023, then soared by 311.73% to $597074.0 in 2024, then grew by 6.86% to $638060.0 in 2025, then decreased by 26.55% to $468678.0 in 2026.
- The last three Interest Expenses figures came in at $468678.0 (Q1 2026), $638060.0 (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | 23.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 975,876.00 |
| Jun 30, 2026 | 975,876.00 |
| Mar 31, 2026 | 468,678.00 |
| Mar 31, 2026 | 468,678.00 |
| Dec 31, 2025 | 638,060.00 |
| Dec 31, 2025 | 638,060.00 |
| Sep 30, 2025 | 6.81 Mn |
| Sep 30, 2025 | 6.81 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 8.15 Mn |
| Mar 31, 2025 | 8.15 Mn |
| Dec 31, 2024 | 597,074.00 |
| Dec 31, 2024 | 597,074.00 |
| Sep 30, 2024 | 7.39 Mn |
| Sep 30, 2024 | 7.39 Mn |
| Jun 30, 2024 | 477,601.00 |
| Jun 30, 2024 | 477,601.00 |
| Mar 31, 2024 | 498,526.00 |
| Mar 31, 2024 | 498,526.00 |